Physician profile
Harry H Lay
NPI 1225177868
$62,781.96
in general payments reported to CMS, 2019-2025
56 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $15K · 2023: $9,364 · 2024: $10K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,738 · Honoraria: $3,250 · Travel and Lodging: $2,753 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,508.10 |
| Consulting Fee | $10,329.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,738.30 |
| Honoraria | $3,250.00 |
| Travel and Lodging | $2,752.58 |
| Education | $173.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $14,477.43 | 2021-2025 | Mavenclad |
| Biogen, INC. | $9,913.65 | 2021-2025 | Tysabri, Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $6,650.86 | 2021-2025 | |
| Genentech USA, INC. | $4,728.53 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Celgene Corporation | $4,694.55 | 2022-2025 | Zeposia |
| Ani Pharmaceuticals, INC. | $4,467.24 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $3,490.49 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,926.74 | 2024-2025 | Zeposia |
| Tg Therapeutics, INC. | $1,390.21 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $1,386.63 | 2023-2025 | Ultomiris, Soliris |
| Abbvie INC. | $1,130.33 | 2021-2025 | |
| Ucb, INC. | $672.09 | 2022-2025 | Briviact, Rystiggo, Nayzilam |
| Lilly USA, LLC | $528.83 | 2022-2025 | Emgality, Amyvid, Kisunla |
| Argenx US, INC. | $475.54 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Merz Pharmaceuticals, LLC | $400.45 | 2022-2025 | Xeomin, Ampyra, Inbrija |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $393.19 | 2022-2025 | Acthar |
| Pfizer INC. | $364.77 | 2023-2025 | |
| Csl Behring | $332.65 | 2022-2025 | Hizentra, Privigen |
| Neurocrine Biosciences, INC. | $320.71 | 2024-2025 | Ingrezza |
| Harmony Biosciences LLC | $318.22 | 2021-2025 | Wakix |
| Acadia Pharmaceuticals INC | $251.56 | 2022-2024 | Nuplazid |
| Vanda Pharmaceuticals INC. | $238.61 | 2024-2025 | Ponvory |
| Amgen INC. | $222.21 | 2022-2025 | Uplizna, Aimovig |
| Banner Life Sciences, LLC | $213.39 | 2022-2024 | |
| Lundbeck LLC | $213.26 | 2022-2025 | Vyepti |
| Axsome Therapeutics, INC. | $197.35 | 2023-2025 | Sunosi, Symbravo |
| Mdd US Operations, LLC | $182.70 | 2023-2025 | Gocovri, Gocovri |
| Jazz Pharmaceuticals INC. | $156.94 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $151.91 | 2022 | |
| Neurelis, INC. | $151.16 | 2023-2025 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $146.73 | 2024-2025 | Hyqvia |
| Avadel Cns Pharmaceuticals, LLC | $143.85 | 2024-2025 | Lumryz |
| Otsuka America Pharmaceutical, INC. | $140.37 | 2023-2025 | Nuedexta, Rexulti |
| Boston Scientific Corporation | $135.73 | 2025 | Wavewriter Alpha Prime 16 |
| Janssen Pharmaceuticals, INC | $132.85 | 2021-2022 | |
| Avion Pharmaceuticals | $126.18 | 2022-2023 | Dhivy |
| Amneal Pharmaceuticals LLC | $108.86 | 2023-2024 | Lyvispah, Rytary |
| Grifols USA, LLC | $93.63 | 2025 | Gamunex-C |
| Acorda Therapeutics, INC | $81.96 | 2022-2024 | Ampyra |
| Horizon Therapeutics Plc | $79.61 | 2021-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $68.19 | 2022-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $65.63 | 2023 | |
| Arbor Pharmaceuticals, INC. | $64.33 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $54.78 | 2023-2024 | Dysport |
| Genentech, INC. | $42.61 | 2022 | |
| Eisai INC. | $33.95 | 2021-2025 | |
| Corium, LLC | $32.35 | 2023 | Adlarity |
| Mylan Specialty L.P. | $32.07 | 2024 | Glatiramer Acetate |
| Catalyst Pharmaceuticals, INC. | $31.07 | 2023 | Firdapse |
| Impel Pharmaceuticals INC. | $24.95 | 2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $20.02 | 2023 | Onpattro |
| Sumitomo Pharma America, INC. | $17.63 | 2023 | Aptiom |
| Aucta Pharmaceuticals, INC. | $16.92 | 2024 | Motpoly Xr |
| Azurity Pharmaceuticals, INC. | $16.71 | 2023 | Horizant |
| Collegium Pharmaceutical, INC. | $15.12 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.66 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Lay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.